Drug intelligence / Profile preview

dingxuan decoction

Development stage: Preclinical
Lead developer: 中国中医科学院望京医院
Administration: Oral

Overview

Dingxuan decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Wangjing Hospital of the China Academy of Chinese Medical Sciences. It is specifically designed for the treatment of vertebral artery type cervical spondylosis (CSA), particularly in patients presenting with the "turbidity of phlegm" syndrome. The formula is intended to resolve phlegm, eliminate dampness, and stabilize vertigo. Clinically, it is used to improve blood flow velocity in the vertebral and basilar arteries, thereby reducing symptoms of dizziness and improving the quality of life for patients with cervical spondylotic arteriopathy.

Other names: dingding decoction

Targets

iGluR (Ionotropic receptor 76b (Ir76b))CaV (Voltage-gated calcium channel protein complex)GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on dingxuan decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dingxuan decoction.

Explore the full profile